Guggenheim Reiterates Buy Rating on SPRB
Guggenheim maintains its buy rating on SPRB, setting a price target of $123, a 146.47% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on SPRB with a $123 price target on June 16, 2026.
- Guggenheim's $123 price target implies 146.47% upside from Spruce Biosciences, Inc.'s ($SPRB) current $49.91 share price.
- SPRB shares traded near $49.91, showing active interest from both insiders and institutional investors.
- Analysts from firms like Jones Trading and HC Wainwright have also issued buy ratings, with targets as high as $200.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on SPRB, setting a price target of $123 on June 16, 2026. The stock is currently trading around $49.91, indicating potential upside according to the analyst's target.
Other Institutional Activity in SPRB
IKARIAN CAPITAL, LLC held steady with 121,356 shares valued at about $7.93 million. Millennium Management LLC initiated a position with 111,888 shares, worth approximately $7.31 million. Citadel Advisors LLC maintained its holding at 69,999 shares, valued at $4.57 million. ADAR1 Capital Management, LLC slightly increased its stake by 600 shares to 58,600 shares, valued at $3.83 million. Wellington Management Group LLP reduced its position by 10,153 shares, now holding 48,796 shares worth $3.19 million.
Spruce Biosciences, Inc. Stock Down 17.9%
SPRB shares are trading near $49.91. The company's recent trading activity has attracted attention from both institutional investors and analysts, with several maintaining or initiating buy ratings.
Insider Buying and Selling at Spruce Biosciences, Inc.
On May 21, 2026, several insiders, including Executive Chairman Michael Grey, purchased 1,700 shares each. Other insiders such as Keli Walbert, Daniel Spiegelman, Percival Barretto-Ko, Camilla Simpson, and Chief Commercial Officer Corwin Dale Hooks also bought shares, with Hooks purchasing 11,000 shares on March 9, 2026.
Analysts Set New Price Targets
On June 16, 2026, Guggenheim reiterated its buy rating on SPRB with a $123 price target. Earlier, on June 9, 2026, Jones Trading initiated coverage with a buy rating and a $135 target. HC Wainwright & Co. maintained its buy rating with a $150 target on June 1, 2026. The consensus among analysts remains positive, with a general buy recommendation and targets ranging from $123 to $283.
About SPRB
SPRB operates in the biotechnology sector, focusing on developing innovative therapies. Headquartered in the United States, the company aims to address unmet medical needs through its research and development efforts.
Bottom Line
Guggenheim's reiterated buy rating and $123 price target on SPRB reflect continued confidence in the company's prospects. The stock's current trading price suggests room for growth, supported by insider buying and positive analyst sentiment. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the most current market conditions.
Get Spruce Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.